-
Uncategorized2 months agoCoultreon banks $125M to support testing of former Galapagos immune drug
Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases. ...
-
Uncategorized2 months ago
Adaptyv Bio reveals latest results in protein design competition
RIO DE JANEIRO, Brazil — For the past two years, Adaptyv Bio has challenged the AI community to see how good today’s models are at designing...
-
Uncategorized2 months agoPredicting consequences of new hepatitis B vaccine recs
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. The other night I watched a...
-
Uncategorized2 months ago
Novartis’ sales dip as generics pressure intensifies, radioequivalents loom
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46%...
-
Uncategorized2 months ago
Lilly strikes second partnership this year for recombinase-based gene editing
Decades before CRISPR gene editing was invented, scientists tried to manipulate genes with enzymes called recombinases. The proteins were precise but proved tricky to use because...
-
Uncategorized2 months ago
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly...
-
Uncategorized2 months ago
Big Pharma–backed Coultreon bags $125M series A to unlock alternative immune pathway
Coultreon Biopharma is advancing assets that target salt-inducible kinases, proteins that drive inflammation and other immune-mediated conditions.
-
Uncategorized2 months ago
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent protections and that the rival has “improperly compared”...
-
Uncategorized2 months agoOpinion: Why do discussions about ‘brain health’ ignore mental illness?
Governments, industry, and philanthropies are investing in neuroscience at an unprecedented scale, and the ambition behind this impetus is a noble one: to reduce the growing...
-
Uncategorized2 months ago
Garijo starts as Sanofi CEO with window to ease reliance on Dupixent
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its...
